Drug Database
UN

unspecified allergy vaccine (Staloral)

✓ Approved

Stallergenes · therapeutic agent

What is unspecified allergy vaccine?

unspecified allergy vaccine is a therapeutic agent developed by Stallergenes. It is approved for therapeutic indications via injectable (others) or oral (po) or subcutaneous injection or sublingual (sl)/oral transmucosal.

Drug Profile

Brand NamesStaloral
CompanyStallergenes
RouteInjectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
StatusApproved
Sources: ClinicalTrials.gov, Stallergenes

Therapeutic Indications

unspecified allergy vaccine is developed for 2 unique indications across 1 therapeutic area.

Therapeutic AreaConditionPhase
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

Related Research Articles

PubMedJournal of general internal medicine2026-10-15

Racial Differences in Respiratory Tract Infection Diagnosis and Antibiotic Prescriptions.

Martinez Kathryn A KA, Rezaee Ava A, Criswell Victoria V, Rothberg Michael B MB

Non-White patients are less likely than White patients to be prescribed antibiotics for respiratory tract infections (RTIs). Our objective was to understand whether this could be explained by differences in RTI diagnosis type by race. We conducted an observational cohort study of adults receiving urgent care at Cleveland Clinic in Northeast Ohio who were diagnosed with an RTI between 2016 and 2022. We used mixed effects logistic regression of antibiotic prescription by patient race (White versus non-White) in two models: 1) not accounting for RTI diagnosis type, and 2) accounting for diagnosis type. We used mixed effects logistic regression, including physician and individual patient as random effects, to assess differences in the odds of being diagnosed with sinusitis versus unspecified RTI by race. Finally, we assessed odds of being prescribed an antibiotic by race, stratified by diagnosis. Analyses were conducted at the visit level. Among 100,052 visits with 62,972 unique patients (median visits per patient was 1), 21% percent were for sinusitis and 30% were for unspecified RTI. Eighty-four percent of patients were White and 16% were non-White. In the model not controlling for diagnosis, compared to White patients, non-White patients were significantly less likely to be prescribed an antibiotic (aOR: 0.79; 95%CI:0.76-0.82). After adjusting for diagnosis, the association between non-White race and antibiotic prescription was weaker but still significant (aOR:0.91; 95%CI:0.87-0.95). Compared to White patients, non-White patients were significantly less likely to be diagnosed with sinusitis versus unspecified RTI (aOR:0.61; 95%CI:0.56-0.66). Non-White patients were significantly less likely to be prescribed antibiotics for sinusitis and unspecified RTI than White patients. Racial differences in diagnosis of sinusitis partially explain lower rates of antibiotic prescription among non-White patients.

PMID 42875615
Read full article →
PubMedImmunological investigations2026-10-15

Rewiring Food Allergy Management: From Allergen Detection to Immune Engineering Therapies.

Meng Jiaqi J, Zhao Leyan L, Wei Qinglin Q, Wei Pengcheng P

Food allergy represents a growing global health challenge, particularly among children in developed countries. Despite decades of research, major barriers persist in both allergen detection and durable immune intervention. This review synthesizes current diagnostic and therapeutic strategies in food allergy, critically evaluates their mechanistic underpinnings and translational readiness. Traditional immunoassays (e.g. enzyme-linked immunosorbent assay, immunoblotting) are sensitive but hindered by matrix interference, operational complexity, and limited real-world applicability. Recent innovations - multi-omics, DNA-based platforms, and portable biosensors - are advancing allergen surveillance toward precision, on-site detection. In parallel, allergen-specific immunotherapies have emerged as proactive strategies for desensitization, yet vary in efficacy, safety, and sustainability. Biologics (e.g. omalizumab, dupilumab) have broadened treatment options, while next-generation platforms - virus-like particle vaccines and microbiome-augmented protocols - are unlocking novel paths toward sustained unresponsiveness. This review outlines an emerging framework of immune engineering poised to redefine the future of allergy care.

PMID 42876274
Read full article →
PubMedCurrent opinion in pediatrics2026-10-15

Using informatics to understand pediatric allergic diseases.

Grunewald Matthew M, Grundmeier Robert W RW, Gabryszewski Stanislaw J SJ

Recent advances in the power, utility, and accessibility of artificial intelligence (AI) have enabled new methods of investigation in the biomedical sciences and opportunities to transform clinical workflows. As allergic conditions are among the most common chronic diseases affecting children, pediatric allergy represents a promising area for AI-augmented informatics methods to support molecular discovery, early identification, risk stratification, treatment customization, and longitudinal monitoring, as reviewed herein. Recent pediatric allergy studies have applied informatics and AI methodologies across various data sources, including molecular and multiomic data, structured and unstructured electronic health record data, environmental exposures, diagnostic images, remote monitoring devices, and patient- and clinician-facing AI tools. Primarily still in the research phase, these approaches include biomarker discovery, disease phenotyping, risk stratification, prediction modeling, remote monitoring, and emerging chatbots for allergy education. Although still relatively nascent within pediatric allergy, AI-augmented informatics shows promise for extracting usable information from complex data and developing tools aimed at personalizing disease detection and management. Most applications remain investigational, and continued progress will require transparency, rigorous validation, generalizability across diverse populations and health systems, feasibility of workflow integration, privacy protection, and longitudinal oversight to ensure continued safety and effectiveness.

PMID 42876409
Read full article →
PubMedThe Permanente journal2026-10-15

A Bibliometric Analysis of Research Interest in Dupilumab for Chronic Rhinosinusitis With Nasal Polyposis.

Huynh Pauline Phuong PP, Kshirsagar Rijul R, Liang Jonathan J

The objective was to evaluate the rapid progress and interest regarding the role of dupilumab in the treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP). The Web of Science Core Collection database was queried in a single day for publications using terms "dupilumab" and a combination of "chronic sinusitis," "rhinosinusitis," and "polyposis" without time restrictions. Document type, years, authors, countries with economic estimates, institutions, journal information, and keywords were analyzed and visualized using VOSviewer. Only original investigation and review articles were included for analysis. Further analysis of the top 10 cited articles were performed. Following deduplication, 358 unique publications were abstracted. Most studies were published in the United States (25.7%), followed by Italy (17.9%) and Japan (9.4%). Studies were most frequently published in the International Forum of Allergy & Rhinology (n = 21) followed by The Journal of Allergy and Clinical Immunology: In Practice (n = 17). B Claus was the most cited author pertaining to this topic, and the most frequent keywords and concepts spanned outcomes, immunology, allergy, and adverse events. Research regarding the use of dupilumab in the treatment of CRSwNP is rapidly evolving, highlighting the paradigm shift in treatment with the introduction of biologic therapy. This analysis showcased global interest in this topic, highlighting hallmark publications and prolific investigators, while also identifying areas for further exploration and collaboration.

PMID 42876213
Read full article →
PubMedPediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology2026-10-15

International survey of parental and patient perspectives on emerging adrenaline devices for community-based management of anaphylaxis: An EAACI task force report.

Gonzalez-Matamala M F MF, Patel N N, Kahn-Santoro D D, Knibb R R et al.

Intranasal adrenaline has been approved in multiple countries for anaphylaxis treatment, based primarily on pharmacokinetic/pharmacodynamic comparisons to adrenaline autoinjectors (AAIs). To assess patient and caregiver perspectives regarding emerging non-injectable adrenaline routes. Online survey of adults and caregivers of children with food allergy prescribed AAIs, with international dissemination supported by the European Academy of Allergy and Clinical Immunology (February-April 2025). We analyzed 542 responses from caregivers and 224 from adults with food allergy. Effectiveness of adrenaline nasal spray (ANS) compared to AAI was rated "extremely important" by 78% of caregivers and 71% of adults. 48% of caregivers and 42% of adults were "extremely worried" that ANS may not work as well as AAI, and 50% and 44% (respectively) that it may not work well enough. Compared with AAI, respondents were less worried about ANS being painful or difficult to carry, and about fear/embarrassment around use, but more worried about side effects and knowing how to use it. Most anticipated being more comfortable using ANS than AAI, and over half anticipated earlier use during anaphylaxis. Only 17.2% of caregivers and 23.2% of adults preferred to be prescribed ANS only. There was interest in sublingual adrenaline due to portability and reduced needle-related burden, but confidence depended on comparable speed/effectiveness and feasibility during reactions. Non-injectable adrenaline is attractive to caregivers and adults, and may improve willingness to carry and use adrenaline. However, demand for evidence of effectiveness, safety, and real-world feasibility is high, highlighting important information needs for shared decision-making.

PMID 42876015
Read full article →
PubMedFrontiers in cellular and infection microbiology2026-10-15

Immunogenicity and protective efficacy of recombinant BCG expressing a multi-epitope vaccine against mycobacterium tuberculosis.

Zhang Xuan-Ji XJ, Luo Jia-Rui JR, Tian Ting-Ting TT, Shi Juan J et al.

Mycobacterium tuberculosis (Mtb) infects approximately one-quarter of the global population, of whom 5%-10% develop active tuberculosis (TB). Although Bacillus Calmette-Guérin (BCG) remains the cornerstone vaccine against severe infant TB, its efficacy in adults is limited, underscoring the need for novel TB vaccines. This study aimed to design a multi-epitope vaccine, tMEV, and validate its protective potential through bioinformatic prediction and in vivo experiments. tMEV was constructed from dominant T- and B-cell epitopes derived from Mtb ESAT-6, PE35, PPE38, and PE4 proteins, fused with an adjuvant. Its vaccine candidacy was assessed via physicochemical and solubility profiling, secondary and tertiary structure modeling, TLR-4 molecular docking, molecular dynamics simulation, and immune simulation. The tMEV coding sequence was cloned into pMV361 and transformed into BCG to generate recombinant BCG (rBCG-tMEV). Immunogenicity, antigenicity, and protective efficacy were evaluated in mouse immunization and Mtb challenge models. tMEV exhibited favorable vaccine-like properties in silico. In mice, both tMEV and rBCG-tMEV induced Mtb-specific immune responses. Compared with PBS, tMEV significantly enhanced cellular and humoral immunity with a Th2-biased profile. Relative to conventional BCG, rBCG-tMEV elicited a superior mixed Th1-Th2 response and higher antigen-specific immunity, accompanied by increased secretion of IFN-γ, IL-2, TNF-α, granzyme B, and perforin. Moreover, rBCG-tMEV markedly reduced bacterial loads in the lungs and spleens of Mtb-infected mice, conferring partial protection. These findings demonstrate that tMEV and rBCG-tMEV possess robust immunogenicity and protective potential against Mtb, representing promising novel TB vaccine candidates and providing a rationale for future vaccine development and optimization.

PMID 42876677
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about unspecified allergy vaccine